Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBP for prevention of episodic migraine
NCT06968429Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in migraine comparing NBP with Placebo (2 arms). Primary endpoint: Change of the average monthly migraine days at 12 weeks. Planned start May 2025; status: not yet recruiting.
02
Drugs
butylphthalide
03
Conditions
migraine
Beyond the preview
Go deeper on NCT06968429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06968429.